TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05890183

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: This systematic cognitive training program will be delivered by telehealth sessions in which each patient logs into their Posit Science account and joins a Zoom videoconference with 4-8 other patients and two cognitive coaches. The first 12 weeks focus on neurocognitive training and the second 12 weeks focus on social cognitive training. Patients have two CT sessions on each of two days each week to complete 4 hours/week of computerized cognitive training for the first 6 months. Thus, each patient will receive 48 hours of neurocognitive training and 48 hours of social cognitive training in the first 6 months. In the second 6 months, the number of hours per week is trimmed to half the dosage.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: This systematic cognitive training program will be delivered by telehealth sessions in which each patient logs into their Posit Science account and joins a Zoom videoconference with 4-8 other patients and two cognitive coaches. The first 12 weeks focus on neurocognitive training and the second 12 weeks focus on social cognitive training. Patients have two CT sessions on each of two days each week to complete 4 hours/week of computerized cognitive training for the first 6 months. Thus, each patient will receive 48 hours of neurocognitive training and 48 hours of social cognitive training in the first 6 months. In the second 6 months, the number of hours per week is trimmed to half the dosage.
Study: NCT06316011

Intervention type: DEVICE
Intervention: Magnetocardiography
Description: Magnetocardiography

Intervention type: DEVICE
Intervention: Magnetocardiography
Description: Magnetocardiography
Study: NCT04660331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Intervention
Description: Undergo communication strategy intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Skills Training
Description: Undergo communication training sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthcare Activity
Description: Participate in interview

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthcare Activity
Description: Undergo environmental scan
Study: NCT06071455

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin
Description: injected distal to the canine on the experimental side.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: injected distal to the canine on the experimental side.
Study: NCT04660331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete survey
Study: NCT04683679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks for 3 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks for 3 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks for 3 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib will be administered twice daily continuously without breaks on a 21-day (3 week) cycle length, for a total of 2 cycles. Olaparib tablets will be administered bid (2 x 150 mg tablets twice daily; total 600 mg daily) on continuous days without interruption for 2 cycles. Each 3 week period constitutes one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib will be administered twice daily continuously without breaks on a 21-day (3 week) cycle length, for a total of 2 cycles. Olaparib tablets will be administered bid (2 x 150 mg tablets twice daily; total 600 mg daily) on continuous days without interruption for 2 cycles. Each 3 week period constitutes one cycle.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: The dose of radiation will be 8-9 Gy x 3 fractions. Radiation therapy will begin on C1D2-7. For tumors that are too large for this schedule, an accomodation of 30 Gy in 6 Gy per fraction is allowed, a schedule commonly used at MSK.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: The dose of radiation will be 8-9 Gy x 3 fractions. Radiation therapy will begin on C1D2-7. For tumors that are too large for this schedule, an accomodation of 30 Gy in 6 Gy per fraction is allowed, a schedule commonly used at MSK.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: The dose of radiation will be 8-9 Gy x 3 fractions. Radiation therapy will begin on C1D2-7. For tumors that are too large for this schedule, an accomodation of 30 Gy in 6 Gy per fraction is allowed, a schedule commonly used at MSK.
Study: NCT05731193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposed group (EXP) - 35 students. EXP group will learn pathological and nonpathological sounds for 3 days.
Description: After 3 days students will take 3 tests with different levels of white noise pollution added ( signal-to-noise ratio (SNR) 20, 40 and none added)
Study: NCT04742374

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling before and after each type of cycle, Single Plasma Exchange or Double Filtration Plasmapheresis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling before and after each type of cycle, Single Plasma Exchange or Double Filtration Plasmapheresis
Study: NCT05560165

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: F-18 sodium fluoride PET/CT guided robotic arm assisted injection of combination of local anesthetic and steroids
Description: A surgical aseptic approach will be followed for the procedure. Local anesthesia of the skin and soft tissue at the entry site will be achieved by 1% lignocaine. A 23G lumbar puncture needle will be introduced and the real-time final placement of the needle will be confirmed with low dose CT (40 mA) fused with pre-procedure PET images. After confirming the real-time position, the local anesthetic and steroid injection (0.5ml of 0.5% Bupivacaine per joint and a total dose of 80mg of Methylprednisolone acetate divided equally based on the number of joints to be injected) will be injected intraarticularly and periarticularly around the target joint through the lumbar puncture needle. The skin entry site will be compressed manually to achieve hemostasis. The same procedure will be repeated if multiple joints are to be injected. After the procedure, patient vitals will be observed for thirty minutes in the recovery area and discharged in stable condition.
Study: NCT06365528

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subcutaneous tunnelling
Description: The Subcutaneous tunnelling group will undergo PICC placement under ultrasonography. Procedures will be implemented under hand hygiene, maximal sterile barrier, and chlorhexidine. The targeted arm will be sterilized with a mixture of chlorhexidine and isopropyl alcohol, and a sterile drape will be placed to cover the entire procedure feld from head to toe and place with additional subcutaneous tunnelling. After vein puncture with the access needle, a Nitinol guidewire will be placed as usual. We will make a tunnel distal to the initial venepuncture site using an additional 14-gauge needle. After resolution of the loop over the venepuncture site, a peel-away sheath will be placed over the wire. The catheter will be trimmed to the distance between the venepuncture site and cavoatrial junction plus the subcutaneous tunnel before being inserted in the usual manner.
Study: NCT05890183

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Program
Description: The Aerobic Exercise Program group sessions will be conducted by Zoom videoconferencing. The group exercise training sessions are a combination of moderate intensity aerobic conditioning (1-min intervals) and moderate to high intensity strength and callisthenic conditioning (1-min intervals). The exercise dosage goal is 150 minutes/week of moderate aerobic activity, over 4 days, including for the first 6 months two group sessions (45 min duration) and two individual sessions personalized to the patient's choice of exercise (30 min duration) in the target heart rate zone. After the first 6 months, the group exercise sessions are once a week but the goal remains 150 minutes/week of moderate exercise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderated Online Social Therapy (MOST)
Description: MOST combines: (1) evidence-based, interactive, user-directed web-based interventions; (2) secure and supportive peer-to-peer web-based social networking; (3) moderator support; and (4) on-demand web chat with registered clinicians. A Motivation Track on the MOST platform will be used to encourage intrinsic motivation for self-improvement for both groups and, for the CT\&E group, involvement in our exercise program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderated Online Social Therapy (MOST)
Description: MOST combines: (1) evidence-based, interactive, user-directed web-based interventions; (2) secure and supportive peer-to-peer web-based social networking; (3) moderator support; and (4) on-demand web chat with registered clinicians. A Motivation Track on the MOST platform will be used to encourage intrinsic motivation for self-improvement for both groups and, for the CT\&E group, involvement in our exercise program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chorus Participatory Text Messaging Program
Description: The Chorus text messaging program is a web-based application that allows clinicians to create a broad range of automated SMS text messages and interactive voice responses using a simple, accessible graphical user interface. It will target encouragement to exercise and social feedback on completed exercise in the CT\&E group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living Group (HLG)
Description: The Healthy Living Group (HLG) meets two sessions/week to discuss wellness, nutrition, insight, recovery, independent living, social skills, and hobbies for the first 6 months and then one session/week for the next 6 months.
Study: NCT05358301

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotic food supplement produced by SYNBIOTEC S.r.l. Each capsule of SYNBIO®slim contains the probiotic strain Lactiplantibacillus Plantarum IMC 510 at a concentration of 15 billion live cells (CFU/capsule). The assumption is of n°1 capsule/day, preferably at breakfast, for 3 months. The capsules can be opened and their content can be dispersed in a cold liquid or at intake temperature or in semi-solid food. Always store in original container or in a clean covered container, out of the reach of children. When stored in a dry, clean environment, out of direct sunlight, the product has a shelf-life of at least 24 months. Samples of probiotic supplement in closed and sealed boxes will be provided to subjects participating at the beginning of the study, in quantities sufficient for the entire duration of the study (90 capsules for 3 months).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: N°1 capsule/day of placebo food supplement (i.e., capsules without added probiotics), with the same intake modalities as probiotic.
Study: NCT04800237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VQW-765
Description: oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsule
Study: NCT06468709

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids
Description: The study subjects were randomly divided into a GC monotherapy maintenance group and a GC combined with MMF maintenance group in a 1:1 ratio. The randomization sequence was generated online using a computer randomization scheme. Group A was the GC monotherapy maintenance group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids+MMF
Description: The study subjects were randomly divided into a GC monotherapy maintenance group and a GC combined with MMF maintenance group in a 1:1 ratio. The randomization sequence was generated online using a computer randomization scheme. Group B was the GC+MMF maintenance group
Study: NCT05967962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Trauma Film Paradigm
Description: Trauma film paradigm is a well-known, validated and established procedure that produces reactions similar to those generated by trauma, and that is often used in research to predict susceptibility for peritraumatic and posttraumatic reactions. In this study the trauma film paradigm will be utilized to simulate combat exposure. The two groups of participants will undergo the trauma film paradigm by watching 16 min traumatic combat scenes vs. non-traumatic movie scenes, respectively. Participants will be given standardized instructions (i.e., ''Imagine you are present at the scene; Do not close your eyes).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: non-traumatic (neutral) film
Description: non-traumatic (neutral) film
Study: NCT05242081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine
Description: S-ketamine 0.5mg/kg for induction and 0.2mg/kg/h for maintenance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Sufentanil 0.2-0.3μg/kg for induction and remifentanil 0.05-0.15μg/kg/min for maintenance
Study: NCT04969783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventilated Cigarette Filter
Description: Ventilated Cigarette Filter
Study: NCT04634994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]SDM-8
Description: PET radiopharmaceutical. Subjects will undergo \[F-18\]SDM-8 PET Scanning to measure synaptic density.
Study: NCT06505382

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound-guided percutaneous neuromodulation
Description: Percutaneous ultrasound-guided neuromodulation of the saphenous nerve in subjects with patellofemoral pain to assess its positive effects on pain and functionality.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous neuromodulation
Description: Percutaneous ultrasound-guided neuromodulation of the saphenous nerve in subjects with patellofemoral pain to assess its positive effects on pain and functionality.
Study: NCT04829487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferol Capsules
Description: Given to subjects 50,000 IU per week for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study: NCT04969783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unventilated Cigarette Filter
Description: Unventilated Cigarette Filter
Study: NCT06354075

Intervention type: OTHER
Intervention: Questionary
Description: Questionary will be administrated to evaluated the information for patients on interventional radiology (explanatory video, information form, etc.).
Study: NCT05721989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziltivekimab B
Description: Participants will receive a single s.c. injection of 15 mg ziltivekimab B (15 mg/mL) by single-use pre-filled manual syringe on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziltivekimab D
Description: Participants will receive a single s.c. injection of 15 mg ziltivekimab D (15 mg/mL) by single-use pre-filled manual syringe on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziltivekimab C
Description: Participants will receive a single s.c. injection of 15 mg ziltivekimab C (30 mg/mL) by single-use pre-filled syringe assembled into a shield-activated pen-injector on Day 1.
Study: NCT06066944

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thai Foot Massage
Description: It is the application of Massage through specific techniques and pressure to the feet and lower legs to promote relaxation, improve circulation, and enhance overall well-being. It is a traditional therapeutic practice originating from Thailand and is often performed by trained practitioners. Thai foot massage is often based on traditional Thai massage techniques. The researcher is duly certified for the administration of Thai Foot Massage.
Study: NCT06464276

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05333263

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treadmetrix
Description: Programmable treadmill that delivers controlled postural disturbances
Study: NCT05633511

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Split Mouth Design
Description: PRF on one side of mouth and CTG on the other side of participant's mouth.
Study: NCT06365528

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-tunnelling
Description: The Non-tunnelling group will have PICC placement with the traditional method under ultrasonography. Procedures will be implemented under hand hygiene, maximal sterile barrier, and chlorhexidine. The targeted arm will be sterilized with a mixture of chlorhexidine and isopropyl alcohol, and a sterile drape will be placed to cover the entire procedure feld from head to toe. After vein puncture with the access needle, a Nitinol guidewire will be placed. After, a peel-away sheath will be placed over the wire. The catheter will be trimmed to the distance between the venepuncture site and cavoatrial junction.
Study: NCT00594373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir gel
Description: 1 gm/100 ml of 1% tenofovir gel vaginally daily
Study: NCT06406673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab+EC/ET+RT
Description: Cohort_1 patients with no history of previous systemic treatment for ES-SCLC received cadonilimab with EC/EP for two cycles (induction phase), then, those who did not progress received concurrent palliative RT and two cycles of cadonilimab with EC/EP (combination phase). Afterward they received cadonilimab every 3 weeks for a maximum of 2 years after study enrolment (maintenance phase).
Study: NCT00594373

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tenofovir gel placebo
Description: 1 gm/100 ml of placebo gel vaginally daily
Study: NCT05509517

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Photoplethysmography based smartphone application for heart rhythm analysis (FibriCheck™)
Description: Heart Rhythm assessment using the FibriCheck™ application with the patient's proprietary smartphone, three times daily, from discharge until follow-up consultation (day 21-91 after discharge).
Study: NCT06194617

Intervention type: DRUG
Intervention: Direct oral anticoagulant
Description: Patients take DOACs according to their condition, with the dosage determined by the clinical physician.
Study: NCT04931979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection [Keytruda]
Description: Up to 17 cycles of pembrolizumab until disease progression, toxicity, death, or withdrawal of IC (whichever occurs first)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Salvage Radiation Therapy (SRT)
Description: SRT according to standard of care (SRT with at least 66 Gy)
Study: NCT06147427

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL reconstruction with hamstrings combined with ALL plasty
Description: ACL reconstruction with hamstrings combined anterolateral plasty using the ALL reconstruction technique (Gracilis throught the femur tunnel of the ACL graft and fixed to the tibia by an anchor on its point of isometry on the tibia).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL reconstruction with hamstrings combined with modified Lemaire's LET
Description: ACL reconstruction with hamstrings combined with modified Lemaire's lateral extra-articular tenodesis technique (Fascia lata strip pedicled to the Gerdy and fixed to the femur throught the tunnel of the ACL graft).
Study: NCT05502445

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: In this group, the steps below are added:on the first day, the delivery of the leaflet on the importance of nutrition in the hospital environment will be added in addition to verbal guidance. On the second day, an educational institutional video with duration of two minutes, will be shown with the title Food Intake and Oral Supplement in Nutritional Rehabilitation via tablet or mobile phone.~When the 24-hour recall will be collected, an assessment of food intake will be performed, mainly of foods that are sources of protein and, when they were less than 75%, strategies must be designed to increase the acceptance or indication of oral nutritional supplements.
Study: NCT06406673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab+vorolanib
Description: Cohort_2 patients with recurrent SCLC and after at most one systemic treatment received cadonilimab plus vorolanib, until disease progression or unacceptable toxicity.
Study: NCT04952870

Intervention type: OTHER
Intervention: Inhaled NO
Description: Newborn or young infants (\< 3 months) receiving inhaled NO as part of their treatment for severe respiratory failure
Study: NCT06321770

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bioactive collagen peptides
Description: 2,5 g collagen peptides

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sachet daily
Study: NCT06578065

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echelon Circular™ Powered Stapler
Description: Echelon Circular™ Powered Stapler will be used in colorectal anastomosis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2-row circular staplers manual
Description: 2-row circular staplers manual will be used in colorectal anastomosis.
Study: NCT05471089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diathermy by emission of Radiofrequency
Description: Applied only to experimental group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic exercise
Description: Applied to both arms/groups
Study: NCT04952870

Intervention type: OTHER
Intervention: routine care
Description: Patients treated for respiratory failure
Study: NCT05300490

Intervention type: DRUG
Intervention: Prednisolone
Description: In this routine care study, all patients will receive a joint injection of prednisolone at a dose left to the discretion of the physician. The urinary excretion kinetics of this product and its metabolites will then be followed at different times. An association with metabolic genetic profile will be done.
Study: NCT04924829

Intervention type: DRUG
Intervention: Tocilizumab
Description: Tocilizumab received as a single intravenous infusion over the period of 60 minutes. Dose of 8 mg/kg, maximum dose of 800 mg.